IKZF1 and neutropenia: The 5/7‐day dosing regimen was designed based on previous avadomide clinical studies, including the dose‐escalation portion of the current study, to mitigate neutropenia by releasing a reversible arrest in neutrophil maturation caused by depletion of Ikaros [20, 33].